Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
- Supplementary File 1:
PDF-Document (PDF, 150 KiB)
Sharma, V.K.; Misra, B.; McManus, K.T.; Avula, S.; Nellaiappan, K.; Caskey, M.; Horowitz, J.; Nussenzweig, M.C.; Seaman, M.S.; Javeri, I.; Dey, A.K. Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. Antibodies 2020, 9, 36. https://doi.org/10.3390/antib9030036
Sharma VK, Misra B, McManus KT, Avula S, Nellaiappan K, Caskey M, Horowitz J, Nussenzweig MC, Seaman MS, Javeri I, Dey AK. Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. Antibodies. 2020; 9(3):36. https://doi.org/10.3390/antib9030036
Chicago/Turabian StyleSharma, Vaneet K.; Misra, Bijay; McManus, Kevin T.; Avula, Sreenivas; Nellaiappan, Kaliappanadar; Caskey, Marina; Horowitz, Jill; Nussenzweig, Michel C.; Seaman, Michael S.; Javeri, Indu; Dey, Antu K. 2020. "Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration" Antibodies 9, no. 3: 36. https://doi.org/10.3390/antib9030036